Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life

Davide Seripa, Andrea Pilotto, Giulia Paroni, Andrea Fontana, Grazia D'Onofrio, Carolina Gravina, Maria Urbano, Leandro Cascavilla, Francesco Paris, Francesco Panza, Alessandro Padovani, Alberto Pilotto

Research output: Contribution to journalArticle

Abstract

It has been suggested that the serotonin or 5-hydroxytriptamine (5-HT) transporter (5-HTT) and its gene-linked polymorphic region (5-HTTLPR) are selective serotonin reuptake inhibitor (SSRI) response modulators in late-life depression (LLD), and particularly in late-life major depressive disorder (MDD). Previous studies differed in design and results. Our study aimed to investigate the solute carrier family 6 (neurotransmitter transporter and serotonin) member 4 (SLC6A4) gene locus, encoding 5-HTT and SSRI treatment response in late-life MDD. For a prospective cohort study, we enrolled 234 patients with late-life MDD to be treated with escitalopram, sertraline, paroxetine or citalopram for 6 months. The SLC6A4 polymorphisms rs4795541 (5-HTTLPR), rs140701 and rs3813034 genotypes spanning the SLC6A4 locus were investigated in blinded fashion. No placebo group was included. We assessed responder or non-responder phenotypes according to a reduction in the 21-item version of the Hamilton Depression Rating Scale (HDRS-21) score of 50%. At follow-up, 30% of the late-life MDD patients were non-responders to SSRI treatment. No time-course of symptoms and responses was made. A poor response was associated with a higher baseline HDRS-21 score. We observed a significant over-representation of the rs4795541-S allele in the responder patients (0.436 versus 0.321; p = 0.023). The single S-allele dose-additive effect had OR = 1.74 (95% CI 1.12-2.69) in the additive regression model. Our findings suggested a possible influence of 5-HTTLPR on the SSRI response in patients with late-life MDD, which is potentially useful in identifying the subgroups of LLD patients whom need a different pharmacological approach.

Original languageEnglish
Pages (from-to)623-633
Number of pages11
JournalJournal of Psychopharmacology
Volume29
Issue number5
DOIs
Publication statusPublished - May 5 2015

Fingerprint

Serotonin Plasma Membrane Transport Proteins
Major Depressive Disorder
Serotonin Uptake Inhibitors
Genes
Serotonin
Citalopram
Depression
Therapeutics
Neurotransmitter Transport Proteins
Alleles
Sertraline
Paroxetine
Cohort Studies
Genotype
Placebos
Prospective Studies
Pharmacology
Phenotype

Keywords

  • Antidepressant drug resistance
  • depression
  • depression management
  • gene polymorphisms
  • geriatrics
  • late-life depression
  • major depressive disorder
  • selective serotonin reuptake inhibitor
  • solute carrier family 6

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Psychiatry and Mental health

Cite this

Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life. / Seripa, Davide; Pilotto, Andrea; Paroni, Giulia; Fontana, Andrea; D'Onofrio, Grazia; Gravina, Carolina; Urbano, Maria; Cascavilla, Leandro; Paris, Francesco; Panza, Francesco; Padovani, Alessandro; Pilotto, Alberto.

In: Journal of Psychopharmacology, Vol. 29, No. 5, 05.05.2015, p. 623-633.

Research output: Contribution to journalArticle

Seripa, D, Pilotto, A, Paroni, G, Fontana, A, D'Onofrio, G, Gravina, C, Urbano, M, Cascavilla, L, Paris, F, Panza, F, Padovani, A & Pilotto, A 2015, 'Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life', Journal of Psychopharmacology, vol. 29, no. 5, pp. 623-633. https://doi.org/10.1177/0269881115578159
Seripa, Davide ; Pilotto, Andrea ; Paroni, Giulia ; Fontana, Andrea ; D'Onofrio, Grazia ; Gravina, Carolina ; Urbano, Maria ; Cascavilla, Leandro ; Paris, Francesco ; Panza, Francesco ; Padovani, Alessandro ; Pilotto, Alberto. / Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life. In: Journal of Psychopharmacology. 2015 ; Vol. 29, No. 5. pp. 623-633.
@article{020736dd248f471eb4cacce83b45496d,
title = "Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life",
abstract = "It has been suggested that the serotonin or 5-hydroxytriptamine (5-HT) transporter (5-HTT) and its gene-linked polymorphic region (5-HTTLPR) are selective serotonin reuptake inhibitor (SSRI) response modulators in late-life depression (LLD), and particularly in late-life major depressive disorder (MDD). Previous studies differed in design and results. Our study aimed to investigate the solute carrier family 6 (neurotransmitter transporter and serotonin) member 4 (SLC6A4) gene locus, encoding 5-HTT and SSRI treatment response in late-life MDD. For a prospective cohort study, we enrolled 234 patients with late-life MDD to be treated with escitalopram, sertraline, paroxetine or citalopram for 6 months. The SLC6A4 polymorphisms rs4795541 (5-HTTLPR), rs140701 and rs3813034 genotypes spanning the SLC6A4 locus were investigated in blinded fashion. No placebo group was included. We assessed responder or non-responder phenotypes according to a reduction in the 21-item version of the Hamilton Depression Rating Scale (HDRS-21) score of 50{\%}. At follow-up, 30{\%} of the late-life MDD patients were non-responders to SSRI treatment. No time-course of symptoms and responses was made. A poor response was associated with a higher baseline HDRS-21 score. We observed a significant over-representation of the rs4795541-S allele in the responder patients (0.436 versus 0.321; p = 0.023). The single S-allele dose-additive effect had OR = 1.74 (95{\%} CI 1.12-2.69) in the additive regression model. Our findings suggested a possible influence of 5-HTTLPR on the SSRI response in patients with late-life MDD, which is potentially useful in identifying the subgroups of LLD patients whom need a different pharmacological approach.",
keywords = "Antidepressant drug resistance, depression, depression management, gene polymorphisms, geriatrics, late-life depression, major depressive disorder, selective serotonin reuptake inhibitor, solute carrier family 6",
author = "Davide Seripa and Andrea Pilotto and Giulia Paroni and Andrea Fontana and Grazia D'Onofrio and Carolina Gravina and Maria Urbano and Leandro Cascavilla and Francesco Paris and Francesco Panza and Alessandro Padovani and Alberto Pilotto",
year = "2015",
month = "5",
day = "5",
doi = "10.1177/0269881115578159",
language = "English",
volume = "29",
pages = "623--633",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life

AU - Seripa, Davide

AU - Pilotto, Andrea

AU - Paroni, Giulia

AU - Fontana, Andrea

AU - D'Onofrio, Grazia

AU - Gravina, Carolina

AU - Urbano, Maria

AU - Cascavilla, Leandro

AU - Paris, Francesco

AU - Panza, Francesco

AU - Padovani, Alessandro

AU - Pilotto, Alberto

PY - 2015/5/5

Y1 - 2015/5/5

N2 - It has been suggested that the serotonin or 5-hydroxytriptamine (5-HT) transporter (5-HTT) and its gene-linked polymorphic region (5-HTTLPR) are selective serotonin reuptake inhibitor (SSRI) response modulators in late-life depression (LLD), and particularly in late-life major depressive disorder (MDD). Previous studies differed in design and results. Our study aimed to investigate the solute carrier family 6 (neurotransmitter transporter and serotonin) member 4 (SLC6A4) gene locus, encoding 5-HTT and SSRI treatment response in late-life MDD. For a prospective cohort study, we enrolled 234 patients with late-life MDD to be treated with escitalopram, sertraline, paroxetine or citalopram for 6 months. The SLC6A4 polymorphisms rs4795541 (5-HTTLPR), rs140701 and rs3813034 genotypes spanning the SLC6A4 locus were investigated in blinded fashion. No placebo group was included. We assessed responder or non-responder phenotypes according to a reduction in the 21-item version of the Hamilton Depression Rating Scale (HDRS-21) score of 50%. At follow-up, 30% of the late-life MDD patients were non-responders to SSRI treatment. No time-course of symptoms and responses was made. A poor response was associated with a higher baseline HDRS-21 score. We observed a significant over-representation of the rs4795541-S allele in the responder patients (0.436 versus 0.321; p = 0.023). The single S-allele dose-additive effect had OR = 1.74 (95% CI 1.12-2.69) in the additive regression model. Our findings suggested a possible influence of 5-HTTLPR on the SSRI response in patients with late-life MDD, which is potentially useful in identifying the subgroups of LLD patients whom need a different pharmacological approach.

AB - It has been suggested that the serotonin or 5-hydroxytriptamine (5-HT) transporter (5-HTT) and its gene-linked polymorphic region (5-HTTLPR) are selective serotonin reuptake inhibitor (SSRI) response modulators in late-life depression (LLD), and particularly in late-life major depressive disorder (MDD). Previous studies differed in design and results. Our study aimed to investigate the solute carrier family 6 (neurotransmitter transporter and serotonin) member 4 (SLC6A4) gene locus, encoding 5-HTT and SSRI treatment response in late-life MDD. For a prospective cohort study, we enrolled 234 patients with late-life MDD to be treated with escitalopram, sertraline, paroxetine or citalopram for 6 months. The SLC6A4 polymorphisms rs4795541 (5-HTTLPR), rs140701 and rs3813034 genotypes spanning the SLC6A4 locus were investigated in blinded fashion. No placebo group was included. We assessed responder or non-responder phenotypes according to a reduction in the 21-item version of the Hamilton Depression Rating Scale (HDRS-21) score of 50%. At follow-up, 30% of the late-life MDD patients were non-responders to SSRI treatment. No time-course of symptoms and responses was made. A poor response was associated with a higher baseline HDRS-21 score. We observed a significant over-representation of the rs4795541-S allele in the responder patients (0.436 versus 0.321; p = 0.023). The single S-allele dose-additive effect had OR = 1.74 (95% CI 1.12-2.69) in the additive regression model. Our findings suggested a possible influence of 5-HTTLPR on the SSRI response in patients with late-life MDD, which is potentially useful in identifying the subgroups of LLD patients whom need a different pharmacological approach.

KW - Antidepressant drug resistance

KW - depression

KW - depression management

KW - gene polymorphisms

KW - geriatrics

KW - late-life depression

KW - major depressive disorder

KW - selective serotonin reuptake inhibitor

KW - solute carrier family 6

UR - http://www.scopus.com/inward/record.url?scp=84930680760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930680760&partnerID=8YFLogxK

U2 - 10.1177/0269881115578159

DO - 10.1177/0269881115578159

M3 - Article

C2 - 25827644

AN - SCOPUS:84930680760

VL - 29

SP - 623

EP - 633

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 5

ER -